A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: healthier (42), improved (762)

Annual-report-24-25-final

Description
2024/25 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2024/25 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-24-25-final.pdf

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description
Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel-PertuzumabTrastuzumab (EC-PPH) Indication • Neo
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Atezolizumab (1875mg 21-days) SC

Description
Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – Atezolizumab monotherapy (1st or 2nd line) Indications • First line
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

UHS AR 23-24 Final

Description
2023/24 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2023/24 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-23-24-Final.pdf

RLP Guidance Notes Cohort 5 Final

Description
University Hospital Southampton Research Leaders Programme (RLP) Award Scheme Application Guidance Notes for Cohort 5 – April 2025 Please complete the application
Url
/Media/Southampton-Clinical-Research/Downloads/RLP-Guidance-Notes-Cohort-5-Final.pdf

Capecitabine-Cisplatin-Trastuzumab

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CAPECITABINE-CISPLATIN-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Capecitabine-Cisplatin-Trastuzumab Indication • Trastuzumab, in combination with capecitabine
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Capecitabine-Cisplatin-Trastuzumab.pdf

Cisplatin-Fluorouracil-Trastuzumab

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CISPLATIN-FLUOROURACIL-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Cisplatin-Fluorouracil-Trastuzumab Indication • Trastuzumab, in combination with cisplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Cisplatin-Fluorouracil-Trastuzumab.pdf

Cemiplimab

Description
Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma in patients
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

Risk-reducing bilateral salpingo-oophorectomy - patient information

Description
This booklet explains what a risk-reducing bilateral salpingo-oophorectomy is and what the operation involves to help you decide whether
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Risk-reducing-bilateral-salpingo-oophorectomy-1434-PIL.pdf
391 to 400 of 455
Previous … 38 39 40 41 42 … Next